The role of dopamine in cognition: Evidence from functional imaging studies

Current Opinion in Neurology

Volumn 16, Issue SUPPL. 2, 2003, Pages

  Remy, Philippe ^a,b   Samson, Yves ^c  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Ageing; Dopamine transporter; Positron emission tomography; Schizophrenia; 18F fluorodopa

Indexed keywords

CARBON 11; DOPAMINE; DOPAMINE RECEPTOR; ECOPIPAM; FLUORINE 18; LEVODOPA; METHYLPHENIDATE; NEUROLEPTIC AGENT; RACLOPRIDE;

AGING; ARTERY CATHETERIZATION; COGNITION; COGNITIVE DEFECT; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; HALLUCINATION; HUMAN; HUNTINGTON CHOREA; IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; RADIOACTIVITY; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOMATOLOGY; WISCONSIN CARD SORTING TEST;

EID: 1342343889     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200312002-00007     Document Type: Review

References (60)

1. Trébossen R, Bendriem B, Ribeiro M-J, et al. Validation of the 3D acquisition mode for the quantitation of [18F]fluorodopa uptake in the human striata with the ETM scatter correction. J Cereb Blood Flow Metab 1998; 18:951-959.
2. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983; 305:137-138.
3. Remy P, de Recondo A, Defer G, et al. Peduncular 'rubral' tremor and dopaminergic denervation: a PET study. Neurology 1995; 45:472-477.
4. Brooks DJ. The early diagnosis of Parkinson's disease. Ann Neurol 1998; 44 (Suppl. 1):S10-S18.
5. 18F]fluoroL-3,4-dihydroxyphenalanine in the primate. J Neurochem 1987; 48:1077-1082.
6. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Row Metab 1985; 5:584-590.
7. Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 1990; 113:1539-1552.
8. 18F]dopa-PET study. Brain 1999; 122:1637-1650.
9. Sawle GV, Myers R. The role of positron emission tomography in the assessment of human neurotransplantation. Trends Neurosci 1993; 16:172-176.
10. Piccini P, Burn DJ, Ceravolo R, et al. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999; 45:577-582.
11. Remy P, Samson Y, Hantraye P, et al. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol 1995; 38:580-588.
12. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996; 19:102-109.
13. Nakamura T, Dhawan V, Chaly T, et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol 2001; 50:181-187.
14. Gjedde A, Reith J, Dyve S, et al. Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci U S A 1991; 88:2721-2725.
15. Kish SJ, Shannak K, Rajput A, et al. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem 1992; 58:642-648.
16. Kish SJ, Zhong XH, Hornykiewicz O, Haycock JW. Striatal 3,4-dihydroxy phenylalanine decarboxylase in aging: disparity between post-mortem and positron emission tomography studies. Ann Neurol 1995; 38:260-264.
17. 18F-dopa uptake: absence of an aging effect. J Cereb Blood Row Metab 1993; 13:881-888.
18. Tedroff J, Ekesbo A, Rydin E, et al. Regulation of dopaminergic activity in early Parkinson's disease. Ann Neurol 1999; 46:359-365.
19. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000; 47:493-503.
20. Ribeiro MJ, Vidailhet M, Loc'h C, et al. Dopaminergic function and dopamine transporter density assessed with PET in Parkinson's disease. Arch Neurol 2002; 59:580-586.
21. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993; 34:423-431.
22. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in parkinson disease. Proc Natl Acad Sci U S A 1993; 90:11965-11969.
23. Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997; 120:2187-2195.
24. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544.
25. 2-dopamine receptors in healthy subjects and antipsy chotic drug-treated patients. Psychopharmacology 1997; 133:396-404.
26. 1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997; 49:717-723.
27. 1 receptor number: a sensitive PET marker for early brain degeneration in Huntington's disease. Eur Arch Psychiatry Clin Neurosurg 1994; 243:249-255.
28. Volkow ND, Wang GJ, Fowler JS, et al. Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 1994; 16:255-262.
29. Volkow ND, Wang GJ, Fowler JS, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997; 386:830-833.
30. Piccini P, Brooks DJ, Björklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999; 2:1137-1140.
31. Koepp MJ, Gunn RN, Lawrence AD, et al. Evidence for striatal dopamine release during a video game. Nature 1998; 393:266-268.
32. de la Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001; 49:298-303.
33. Volkow ND, Wang GJ, Fowler JS, et al. 'Nonhedonic' food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse 2002; 44:175-180.
34. Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990; 10:740-747.
35. Thaker GK, Carpenter WT Jr. Advances in schizophrenia. Nat Med 2001; 7:667-671.
36. Owen AM, James M, Leigh PN, et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992; 115:1727-1751.
37. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990; 13:266-271.
38. Javoy-Agid F, Ploska A, Agid Y. Microtopography of tyrosine hydroxylase, glutamic acid decarboxylase, and choline acetyltransferase in the substantia nigra and ventral tegmental area of control and Parkinsonian brains. J Neurochem 1981; 37:1218-1227.
39. Broussolle E, Dentresangle C, Landais P, et al. The relation of putamen and caudate nucleus 18F-dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci 1999; 166:141-151.
40. 18F]fluorodopa positron emission tomographic study. Arch Neurol 2000; 57:470-475.
41. Remy P, Jackson PL, Ribeiro MJ, et al. Relationships between cognitive deficits and dopaminergic function in the striatum of Parkinson's disease patients: a PET study [Abstract]. Neurology 2000; 54 (Suppl. 3):A372.
42. Holthoff-Detto VA, Kessler J, Herholz K, et al. Functional effects of striatal dysfunction in Parkinson disease. Arch Neurol 1997; 54:145-150.
43. Marié RM, Barre L, Dupuy B, et al. Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease. Neurosci Lett 1999; 260:77-80.
44. 123I] beta-CIT SPECT and prefrontal cognitive functions in Parkinson's disease. J Neural Transm 2000; 107:303-319.
45. Owen AM, Doyon J, Dagher A, et al. Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions. Brain 1998; 121:949-965.
46. Dagher A, Owen AM, Boecker H, Brooks DJ. The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease. Brain 2001; 124:1020-1032.
47. Cools R, Stefanova E, Barker RA, et al. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002; 125:584-594.
48. Mattay VS, Tessitore A, Callicott JH, et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 2002; 51:156-164.
49. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001; 11:1136-1143.
50. Dao-Castellana M-H, Paillère-Martinot M-L, Hantraye P, et al. Heterogeneous presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 1997; 23:167-174.
51. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997; 94:2569-2574.
52. 1 receptors in schizophrenia revealed by PET. Nature 1997; 385:634-636.
53. Dolan RJ, Fletcher P, Frith CD, et al. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 1995; 378:180-182.
54. Fletcher PC, Frith CD, Grasby PM, et al. Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia. J Neurosci 1996; 16:7055-7062.
55. Celsis P. Age-related cognitive decline, mild cognitive impairment or preclinical Alzheimer's disease? Ann Med 2000; 32:6-14.
56. Small SA. Age-related memory decline: current concepts and future directions. Arch Neurol 2001; 58:360-364.
57. 11C] raclopride. J Cereb Blood Flow Metab 1993; 13:310-314.
58. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol 1994; 36:237-239.
59. Volkow ND, Gur RC, Wang GJ, et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry 1998; 155:344-349.
60. Mozley LH, Gur RC, Mozley PD, Gur RE. Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 2001; 158:1492-1499.